ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 165 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2017. The put-call ratio across all filers is 1.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $861 | +34.1% | 18 | 0.0% | 0.00% | – |
| Q3 2023 | $642 | -35.8% | 18 | +50.0% | 0.00% | – |
| Q2 2022 | $1,000 | 0.0% | 12 | 0.0% | 0.00% | – |
| Q4 2021 | $1,000 | -100.0% | 12 | -76.5% | 0.00% | – |
| Q3 2017 | $2,716,000 | -12.6% | 51 | +2.0% | 0.00% | – |
| Q2 2017 | $3,106,000 | -98.7% | 50 | -98.6% | 0.00% | -100.0% |
| Q1 2017 | $236,552,000 | – | 3,490 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |